Skip to main content
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Mar 1;154(5):705–707.

Compound could help diabetic patients walk tightrope between heperglycemia, hypoglycemia.

F Lowry
PMCID: PMC1487539  PMID: 8603330

Abstract

A pharmaceutical company is proceeding with clinical testing of a new compound that could make it easier for diabetic patients to maintain good control of blood-sugar levels. The compound, a peptide called amylin, appears to lessen wild fluctuations in blood-glucose levels by slowing the rate of gastric emptying and moderating the amount of postprandial glucose. Fran Lowry interviewed the researcher who discovered the peptide.

Full text

PDF
705

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES